Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients
暂无分享,去创建一个
K. Nackaerts | F. Mottaghy | K. Haustermans | E. Van Cutsem | C. Verslype | K. Bogaerts | C. Deroose | A. Verbruggen | M. Koole | K. Baete | P. Clement | C. Terwinghe | Sofie Van Binnebeek | B. Vanbilloen
[1] Liane Oehme,et al. The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG , 2013, EJNMMI Research.
[2] O. Nanni,et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[3] F. Minuto,et al. Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for , 2012, Journal of Endocrinological Investigation.
[4] F. Mottaghy,et al. Functional imaging of neuroendocrine tumors. , 2011, Methods in molecular biology.
[5] P. Cumming,et al. 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors , 2010, The Journal of Nuclear Medicine.
[6] J. Yap,et al. Comparison of standardized measurement of SUVmax versus a threshold-based SUVmean in cancer response assessment using FDG-PET , 2010 .
[7] V. Cuccurullo,et al. The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[8] M. Pawlikowski,et al. SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. , 2010, Folia histochemica et cytobiologica.
[9] R. Bale,et al. Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy , 2009, Journal of Nuclear Medicine.
[10] R. Jensen,et al. Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.
[11] A. Runz,et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[12] R. Bale,et al. 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.
[13] Anders Sundin,et al. Nuclear imaging of neuroendocrine tumours. , 2007, Best practice & research. Clinical endocrinology & metabolism.
[14] A. Balbarini,et al. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages , 2007, Journal of leukocyte biology.
[15] Uwe Haberkorn,et al. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[16] Ludwig G Strauss,et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] R. Boellaard,et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] W. H. Knapp,et al. 68Ga-labelled DOTA-derivatised peptide ligands , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[19] Christian Bruns,et al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects , 2003, Nature Reviews Drug Discovery.
[20] Uwe Haberkorn,et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[21] P. Schöffski,et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.
[22] U. Haberkorn,et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] J. Reubi,et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.
[24] L G Strauss,et al. The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.